Core Viewpoint - The newly launched oral six-valent rotavirus vaccine developed by Wuhan Institute of Biological Products is the first of its kind globally, offering higher safety and efficacy, and is expected to be available for vaccination by the end of December [1][2]. Group 1: Vaccine Development and Features - The six-valent rotavirus vaccine took 18 years from research to production and is designed to prevent severe rotavirus diarrhea caused by six serotypes: G1, G2, G3, G4, G8, and G9 [1]. - This vaccine fills the gap in protection against the G8 strain, which has been prevalent in Asia, and provides a solution for global infant diarrhea prevention [1]. - The vaccine has an annual production capacity of 24 million doses, sufficient to meet the needs of infants in China [2]. Group 2: Clinical Efficacy - Phase III clinical trials involving 6,400 participants demonstrated a protection efficacy of 85.72% against severe rotavirus gastroenteritis [2]. - The vaccine shows a 100% efficacy rate against severe diarrhea caused by the G8 strain, significantly reducing the risk of severe cases and hospitalizations in infants [2]. - It is expected that after completing the vaccination schedule, the incidence of severe rotavirus diarrhea in children under five years old in China could decrease by over 80% [2]. Group 3: Vaccination Recommendations - The vaccine is recommended for infants aged 6 weeks to 3 years, with the vaccination process requiring three oral doses to be completed by 36 weeks of age [2]. - Despite being a voluntary Category 2 vaccine, it is emphasized as the most effective method for preventing rotavirus diarrhea, and early vaccination is encouraged [2].

Group 1 - The core point of the article is the introduction of the world's first oral six-valent reconfigured rotavirus attenuated live vaccine developed by the Wuhan Institute of Biological Products, which is set to be available for administration by the end of December this year [1] Group 2 - The vaccine is based on Vero cell technology, indicating a significant advancement in vaccine development within the industry [1] - The launch of this vaccine represents a milestone in the fight against rotavirus, which is a leading cause of severe diarrhea in children [1] - The rapid timeline for availability suggests a proactive approach by the company to address public health needs [1]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][9][30] Core Views - The vaccine industry is currently facing performance pressure in 2024 and Q1 2025, with inventory turnover and accounts receivable turnover needing improvement. The industry is still in a bottoming process due to high competition and declining prices for some products. Demand is also affected by consumer fatigue and insufficient market education, leading to a supply-demand imbalance [9][30] - The industry is actively adjusting pipeline layouts, focusing on technological iteration and innovative vaccines, while increasing R&D efforts for multi-valent products. In the long term, product innovation remains the core of competitive strength, with a focus on innovation and international expansion [9][30] Summary by Sections Recent Developments - Six vaccine companies have released their semi-annual reports, with four companies showing positive revenue growth and three companies reporting positive net profit growth attributable to shareholders. The upcoming week will see a concentrated release of semi-annual reports from vaccine companies, warranting attention to their performance [4][10] Market Performance - The vaccine sector saw a 4.41% increase last week, ranking second among the pharmaceutical sub-sectors. Year-to-date, the cumulative increase in the vaccine sector has expanded to 6.79% [5][12] Company Performance - The top-performing companies in the vaccine industry last week included Olin Bio, Wantai Bio, and Kangtai Bio, while the underperformers included Kanghua Bio and Zhifei Bio [6][12] Valuation - The vaccine sector's PE (ttm) was 85.49X, up by 3.67X week-on-week, with a one-year maximum of 85.49X and a minimum of 19.57X. The PB (lf) was 2.09X, also showing a week-on-week increase [7][8] Investment Recommendations - The report emphasizes the importance of focusing on companies with strong R&D capabilities and technological advantages, recommending Kangxino for its innovation strength and Kanghua Bio for its demand stability. Attention is also drawn to the upcoming semi-annual reports and changes in inventory and accounts receivable [10][30]